Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07584226 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
A Phase 1 study, sponsored by Relay Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT07584226 is a Phase 1 study that is actively recruiting participants, run by Relay Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT07584226, a Phase 1 study, is actively recruiting participants, sponsored by Relay Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.
Interventions
- DRUG RLY-8161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07584226
The ClinicalTrials.gov registry entry for NCT07584226 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Relay Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RLY-8161 is the first listed.
NCT07584226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07584226 about?
NCT07584226 is a clinical study titled "A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors". This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumor...
What is the current status of trial NCT07584226?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2026-03-09. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT07584226?
The interventions under investigation include: RLY-8161 (DRUG).
Who is sponsoring clinical trial NCT07584226?
This trial is sponsored by Relay Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.